Benzothienopyridines for use as inhibitors of Eg5 kinesin

Details Benzothienopyridines for use as inhibitors of Eg5 kinesin Benzothienopyridines for use as inhibitors of Eg5 kinesin

2010-03-30

2011-10-25

Kifle, Bruck (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

08044065

ABSTRACT:
Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

REFERENCES:
patent: 6890933 (2005-05-01), Feng et al.
patent: 2003/0113822 (2003-06-01), Westwood et al.
patent: 2003/0114432 (2003-06-01), Clare et al.
patent: 2004/0242596 (2004-12-01), Kim
patent: 2005/0004156 (2005-01-01), Feng et al.
patent: 2007/0232596 (2007-10-01), Vennemann et al.
patent: 0 357 122 (1990-03-01), None
patent: WO 96/32003 (1996-10-01), None
patent: WO 02/28865 (2002-04-01), None
patent: WO 2004/004652 (2004-01-01), None
patent: WO 2004/111193 (2004-12-01), None
patent: PCT/EP2005/054054 (2005-11-01), None
patent: WO 2006/086358 (2006-08-01), None
patent: PCT/EP2007/051688 (2007-05-01), None
patent: PCT/EP2007/051691 (2007-05-01), None
patent: PCT/EP2007/055846 (2007-06-01), None
patent: WO 2007/144384 (2007-12-01), None
patent: PCT/EP2007/057195 (2008-01-01), None
patent: WO 2008006883 (2008-01-01), None
Hammam, A., et al. “Synthesis of Novel Tricyclic Heterocyclic Compounds as Potential Anticancer Agents Using Chromanone and Thiochromanone as Synthons.” (Indian Journal of Chemistry), 2003, 1985-1993, 42B.
Toth, G., et al. “Fused Heterocycles. Part 3. Synthesis and Stereochemistry of Benzopyrano-and Benzothiapyrano-[4, 3-c] Pyrazoles.” (Journal of the Chemical Society), 1989, 319-323, 2.
“GI50 Mean Graph for Compound 652810-NCI Cancer Screen Aug. 2004 Data.” (DTP Warehouse), 2004, 1, XP002420061.
Sunder-Plassmann, N., et al. “Synthesis and biological evaluation of new tetrahydro-Beta-carbolines as inhibitors of the mitotic kinesin Eg5,” Bioorganic & Medicinal Chemistry, vol. 13, pp. 6094-6111 (2005).
Blicke and D. Sheets, “Derivatives of Thianaphthene,”J. Am. Chem, Soc., v. 70, pp. 3768-3770, 1948.
Marcus et al., “Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells.”J. Biol. Chem., v.280:12, pp. 11569-11577, 2005.
Hotha et al., “HR22C16: A Potent Small-Molecule Probe for the Dynamics of Cell Division.”Angew. Chem., v.115, pp. 2481-2484, 2003.
Avakian et al., “The Synthesis and Microbiological Properties of β-(2-Benzothienyl)-α-aminopropionic Acid.”J. Am. Chem. Soc., v.70, pp. 3075-3076, 1948.
Roschke Anna V., et al., “Karyotypic Complexity of the NCI-60 Drug-Screening Panel”, Cancer Research 63, 8634-8647, Dec. 15, 2003.

Affiliated with

Also associated with

Rating

Benzothienopyridines for use as inhibitors of Eg5 kinesin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzothienopyridines for use as inhibitors of Eg5 kinesin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothienopyridines for use as inhibitors of Eg5 kinesin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4282722